List of Zmax drug patents

Zmax is owned by Pf Prism Cv.

Zmax contains Azithromycin.

Zmax has a total of 2 drug patents out of which 0 drug patents have expired.

Zmax was authorised for market use on 10 June, 2005.

Zmax is available in for suspension, extended release;oral dosage forms.

Zmax can be used as method of treating bacterial infections.

The generics of Zmax are possible to be released after 14 February, 2024.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6984403 PF PRISM CV Azithromycin dosage forms with reduced side effects
Feb, 2024

(1 year, 6 days from now)

US7887844 PF PRISM CV Multiparticulate crystalline drug compositions having controlled release profiles
Feb, 2024

(1 year, 6 days from now)

Drugs and Companies using AZITHROMYCIN ingredient

Market Authorisation Date: 10 June, 2005

Treatment: Method of treating bacterial infections

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic